833 related articles for article (PubMed ID: 21062104)
1. Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG
Pharmacoeconomics; 2011 Mar; 29(3):225-37. PubMed ID: 21062104
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
Inotai A; Mészáros A
Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.
Capel M; Tornero J; Zamorano JL; Oyagüez I; Casado MÁ; Sánchez-Covisa J; Lanas A
Reumatol Clin; 2014; 10(4):210-7. PubMed ID: 24380809
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
[TBL] [Abstract][Full Text] [Related]
11. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
12. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
Al MJ; Maniadakis N; Grijseels EW; Janssen M
Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
[TBL] [Abstract][Full Text] [Related]
13. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
14. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
15. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
Brereton N; Winn B; Akehurst R
J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
20. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
